Asset Details
Do you wish to reserve the book?
Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis
Do you wish to request the book?
Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis
2013
Overview
Little evidence is available on the pharmacokinetics of antituberculous medication in premature infants. We report rifampicin (RMP) pharmacokinetics in an extremely premature, low-birthweight female infant born to a mother with known miliary tuberculosis. Intravenous RMP, isoniazid (INH), ciprofloxacin and amikacin were used, as the enteral route was not possible. Area under the curve calculations revealed low average RMP concentrations at doses of 5–10 mg/kg. We review the literature with regard to the dosing regimen and therapeutic drug levels of RMP and INH in premature infants and discuss issues of management. Evidence from this case suggests 10 mg/kg/day is the minimum dose required.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Antibiotics, Antitubercular - blood
/ Antibiotics, Antitubercular - pharmacokinetics
/ Antibiotics, Antitubercular - therapeutic use
/ Antitubercular Agents - therapeutic use
/ Babies
/ Black
/ Enzymes
/ Female
/ Humans
/ Infectious Disease Transmission, Vertical
/ Neonate
/ Respiratory distress syndrome
/ Studies
/ Toxicity
/ Tuberculosis, Miliary - congenital
/ Tuberculosis, Miliary - drug therapy
